Você procurou por: pazjienti (Maltês - Inglês)

pazjienti kollha
all patients

pazjienti b ’ immunodeffiċenzja.
patients with immunodeficiencies.

populazzjoni ta’ pazjienti imp24011
patient population imp24011

pazjienti bi passat ta’ kankru.
patients with history of malignancies.

pazjienti li ma kienux ikkontrollati ma, li
patients who are not controlled by,

pazjienti b’indeboliment tal-kliewi jew tal -fwied
patients with renal or hepatic impairment

pazjienti b’ tuberkulosi attiva u infezzjonijiet severi oħrajn.
patients with active tuberculosis and other severe infections.

raptiva jrid jintuża b’attenzjoni f’dawn il-pazjienti.
raptiva should be used with caution in this patient population.

erbgħa minn dawn il-pazjienti kellhom sinjali kliniċi ta’ tromboċitopenja.
four of these patients had clinical signs of thrombocytopenia.

komuni: effetti oħra li jistgħu jseħħu fi 1-10 pazjienti minn 100;
common: side effects that may occur in 1 to 10 out of 100 patients;

fuq kollox, inqas minn 1% ta pazjienti waqqaf il-kura minħabba simptomi.
overall less than 1% of patients discontinued therapy because of acute flu-like symptoms.

dawn il- problemi jistgħu jaffetwaw bejn 1 u 10 pazjienti f’ 100 li ġew ittratti.
these problems may affect between 1 and 10 patients out of 100 treated.

dawn is-simptomi naqqsu wara dan, għal perċentaġġ li huwa komparabbli għal pazjienti ikkurati minn plaċebo.
these symptoms diminished thereafter to a percentage comparable to that of patients treated with placebo.

m’għandekx tagħti neulasta lil pazjienti bi storja ta’ ipersensitivita g ħal pegfilgastrim jew filgastrim.
do not administer neulasta to patients with a history of hypersensitivity to pegfilgrastim or filgrastim.

pazjienti ma jistgħux jirċievu tilqima li huma live jew live-attenuated waqt il-kura ma’ raptiva.
patients should not receive live and live-attenuated vaccines while on raptiva therapy.

is- soluzzjoni rrikostituta hija għall- użu tiegħek u ma tistax tagħtiha lill- pazjienti oħra. tiegħek.
the reconstituted solution is for your use alone and should not be administered to other patients.

il-kura jista jitkompli biss f’dawk il-pazjienti li jirrispondu b’mod adegwat g]al kura.
therapy may be continued only in those patients who respond adequately to treatment.

f’dan in-numru iżgħar ta’ pazjienti ma ġewx osservati xi differenżi la fil-parametri farmakodinamiċi jew farmaokokientiċi.
in this small number of patients no differences were observed in either pharmacodynamic or pharmacokinetic parameters.

il-kura jista jkun kontinwat biss f’dawk il-pazjienti li jrispondew għal trattament (pga tajjeb jew aħar).
therapy may be continued only in patients who responded to treatment (pga good or better).

ma ġewx osservati differenzi fis-sigurta jew effikaċja bejn l-anzjani ( 65 sena) u pazjienti aktar zg]ar.
no differences in safety or efficacy were observed between elderly ( 65 years) patients and younger patients.